Revisiting Stock Picks Intel, Progressive, Bristol Myers Squibb
Technical indicators show encouraging signs for the three stocks.
Fiscal Year: January - December
Bristol-Myers Squibb Company (BMY), listed on the NYSE, has a market capitalization of $118.32B. As of Jul 10, 2026, the stock is trading at $57.94 per share@else an unavailable price , offering investors a clear view of its current market value. Bristol-Myers Squibb Company is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 16.22, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Bristol-Myers Squibb Company also offers a dividend yield of 4.35%, making it an attractive option for income-focused investors who seek regular dividends.
DCF analysis data is not yet available for Bristol-Myers Squibb Company (BMY). The fair value estimate will be displayed once sufficient analyst forecast data is collected.
The proprietary SS Score for Bristol-Myers Squibb Company is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Bristol-Myers Squibb Company, Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Bristol-Myers Squibb Company is 9.94, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Bristol-Myers Squibb Company (BMY) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Bristol-Myers Squibb Company (BMY) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. It is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Bristol-Myers Squibb Company (BMY) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Bristol-Myers Squibb Company. To access the full SS Score, consider upgrading your subscription.
Bristol-Myers Squibb Company is a significant player in the industry sector, with a market capitalization of $118.32B and a competitive P/E ratio of 16.22. Investors should compare these metrics with industry peers to gauge whether Bristol-Myers Squibb Company is outperforming or underperforming within its sector.
Technical indicators show encouraging signs for the three stocks.
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026.
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Dividend.
#TheMorningFilter #PortfolioRebalance #StockInvesting These value stocks can balance portfolios heavy in growth stocks—and they're undervalued, too. Watch The Morning Filter: https://www.youtube.com/l...
Japan's Takeda Pharmaceutical said on Thursday its experimental once-daily psoriasis pill, developed with the help of AI, outperformed Bristol Myers Squibb's approved drug Sotyktu in a late-stage hea...
Industries from semiconductors to fiber-optic cables stand to benefit from space research and manufacturing, but experts told CNBC that medicine could see the most immediate disruption. A flurry of co...
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMY--Mariska Hargitay Partners with BMS for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease.
Arcus Biosciences (RCUS) announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (BMY). Under the agreement, Arcus will supply casdatifan, the company’s investigational...
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...
SystImmune and Bristol Myers (BMY) Squibb announced that SystImmune’s parent company, Sichuan Biokin Pharmaceutical, reported results from prespecified interim analyses of two Phase 3 studies evaluati...
REDMOND, Wash. & PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival.
Bristol Myers (BMY) Squibb announced that the European Commission has approved Opdivo in combination with doxorubicin, vinblastine and dacarbazine for the treatment of adult and adolescent patients 12...
Bristol Myers (BMY) Squibb announced the U.S. Food and Drug Administration FDA accepted a supplemental New Drug Application for Camzyos as a potential treatment for adolescents with symptomatic obstru...
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CAMZYOS--US FDA Accepts for Priority Review Bristol Myers Squibb's Supplemental New Drug Application for Camzyos to Treat Adolescents with oHCM.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #HodgkinLymphoma--BMS Announces Opdivo (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Ly...
BioNTech SE (BNTX) and Bristol Myers Squibb Company (BMY) announced interim Phase 2 data from the global Phase 2/3 ROSETTA Lung-02 clinical trial evaluating the investigational PD-L1xVEGF-A bispecific...
Shares of C4 Therapeutics (CCCC) are up 19%, or 70c, to $4.36 in midday trading after Bristol Myers (BMY) announced positive Phase 3 multiple myeloma data.
Bristol Myers (BMY) Squibb announced late-breaking results from the Phase 3 SUCCESSOR-2 trial of CELMoD mezigdomide in combination with carfilzomib and dexamethasone versus carfilzomib and dexamethaso...
Bristol Myers Squibb said on Friday that its experimental oral drug mezigdomide delayed disease progression in a late-stage trial of multiple myeloma patients whose illness had relapsed or not respon...
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--BMS Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in.
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--BMS to Unveil New Data at ASCO 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline.
Bristol Myers Squibb ($BMY), a large U.S. drug firm focused on cancer, blood, and immune disease drugs, is teaming up with Anthropic to bring its Claude AI model to more…
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.